BioSpace11d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
GH Research initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan initiated coverage of GH Research (GHRS) with an Overweight rating and no price target GH Research is ...
Cantor Fitzgerald sets GH Research stock Overweight, $14 target
GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients. Read more on ATAI stock update.
BioWorld11d
Compass points true north for GH’s phase IIb depression trial
Major strides for the company on two fronts – psychedelic therapies and treatment-resistant depression (TRD) – came in the ...
CNN1y
GH Research Plc
or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.